Bioventix

BVXP · AIM · Health Care · mcap £95m · 1825.0p

Beta Briefing, track record and signals & risks are not ready for Bioventix yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 61 companies are already wired into a briefing: browse them.

All announcements Monitoring checked today, 12:35

All · 18 Key · 4

Date	Type	Announcement	Day
24 Jun 26	Director dealing	Director/PDMR Shareholding
18 May 26	Holding	Holding(s) in Company
28 Apr 26	Director dealing	Director/PDMR Shareholding
20 Apr 26		Share Options Awarded Share options awarded to CEO and CFO under Share Option Plan 2020.	+0.0%
13 Apr 26	Director dealing	Director/PDMR Shareholding
08 Apr 26	Director dealing	Director/PDMR Shareholding
02 Apr 26	Director dealing	Director/PDMR Shareholding
02 Apr 26	Holding	Holding(s) in Company
30 Mar 26	Results	Half-year Results H1 FY26 revenue £6.16m, profit before tax £4.85m, tau/neuro royalties five-fold to £150k.	+6.9%
24 Feb 26	Board change	Appointment of Non-Executive Director Chris Yates appointed as independent Non-Executive Director with effect from 1 March 2026.	+0.0%
04 Dec 25	Routine	Result of AGM
26 Nov 25	Director dealing	Director/PDMR Shareholding
18 Nov 25	Holding	Holding(s) in Company
11 Nov 25	Routine	Posting of Annual Report and Notice of AGM
04 Nov 25	Director dealing	Director/PDMR Shareholding
30 Oct 25	Director dealing	Director/PDMR Shareholding
27 Oct 25	Director dealing	Director/PDMR Shareholding
27 Oct 25	Results	Results for the year ended 30 June 2025 Revenue down 4% to £13.1m, profit before tax down 5% to £10.1m; second interim dividend 80p per share announced.	−15.7%

Company filings. Not investment advice.